ArticleJournal of diabetes and metabolic disorders2026
Assessment of plasma glycated CD59 in type 2 diabetic patients with diabetic retinopathy and nephropathy: a study of combined microvascular complications.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy and diabetic nephropathy are major microvascular complications of type 2 diabetes mellitus and may progress silently before clinical detection. Plasma glycated CD59 has been proposed as a marker linked to complement-mediated endothelial injury. This study assessed plasma glycated CD59 levels in type 2 diabetic patients with retinopathy, nephropathy, and combined microvascular complications. Methods: This cross-sectional observational study included 420 patients with type 2 diabetes mellitus. Participants were divided into four groups: diabetes without microvascular complications ( Results: The mean age was 56.8 ± 9.4 years, and the mean diabetes duration was 8.9 ± 5.1 years. Plasma glycated CD59 was highest in patients with combined retinopathy and nephropathy (12.8 ± 3.6 AU/mL), followed by nephropathy alone (10.4 ± 2.9 AU/mL), retinopathy alone (9.6 ± 2.7 AU/mL), and diabetes without complications (6.2 ± 1.8 AU/mL). Plasma glycated CD59 correlated positively with glycated haemoglobin ( Conclusion: Plasma glycated CD59 levels were higher in patients with type 2 diabetes who had microvascular complications, particularly in those with both diabetic retinopathy and diabetic nephropathy. These findings indicate that plasma glycated CD59 may be useful as an additional marker for assessing the burden of diabetic microvascular disease. However, as the study was cross-sectional, the results should not be interpreted as evidence of causation or prediction. Further prospective studies are needed to confirm its clinical usefulness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.